Traws Pharma Highlights Positive Ratutrelvir Phase 2 COVID-19 Data

Traws Pharma ( (TRAW) ) has issued an update.

On February 19, 2026, Traws Pharma reported completion of the clinical analysis of a 90-patient open-label Phase 2 study of ratutrelvir versus PAXLOVID in mild-to-moderate COVID-19, including a separate arm of PAXLOVID-ineligible patients at elevated risk of severe disease. Ratutrelvir showed a differentiated profile with fewer treatment-related adverse events, faster symptom resolution in PAXLOVID-ineligible subjects and no observed viral rebounds, reinforcing its potential role in acute COVID-19 and possibly in reducing Long COVID risk.

The company also outlined progress on tivoxavir marboxil, where a new tablet formulation achieved substantially higher exposure in preclinical work and is expected to support once-monthly prophylaxis against seasonal influenza, with a PK study submitted in Australia and plans for a UK prophylaxis challenge study. In a setback for its U.S. program, the FDA placed the tivoxavir marboxil IND on clinical hold over mutagenicity concerns, which does not halt ex-U.S. trials but injects regulatory uncertainty into Traws Pharma’s efforts to secure U.S. strategic stockpile inclusion and could influence timelines and risk perceptions for investors and partners.

The most recent analyst rating on (TRAW) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Traws Pharma stock, see the TRAW Stock Forecast page.

Spark’s Take on TRAW Stock

According to Spark, TipRanks’ AI Analyst, TRAW is a Neutral.

The score is held back primarily by weak financial performance (widening losses, rising cash burn, and negative equity), which elevates funding risk. Offsetting this are strong technical momentum (price above major moving averages with positive MACD) and multiple positive corporate catalysts tied to COVID and influenza pipeline progress, while valuation metrics are not supportive/meaningful given the loss-making profile.

To see Spark’s full report on TRAW stock, click here.

More about Traws Pharma

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing novel oral small-molecule antivirals targeting critical respiratory viral threats, including COVID-19, Long COVID and bird flu. The company integrates antiviral drug development, medical intelligence and regulatory strategy, aiming at difficult-to-treat or resistant virus strains in multi-billion-dollar COVID-19 and seasonal influenza markets.

Its pipeline includes ratutrelvir, an oral Mpro/3CL protease inhibitor designed to treat SARS-CoV-2 without ritonavir, and tivoxavir marboxil, a CAP-dependent endonuclease inhibitor being developed as a single-dose treatment for bird flu and seasonal influenza. Both candidates have shown broad in vitro activity against diverse viral strains, supporting Traws Pharma’s positioning in pandemic preparedness and strategic stockpiling-driven demand.

Average Trading Volume: 314,488

Technical Sentiment Signal: Sell

Current Market Cap: $15.66M

For detailed information about TRAW stock, go to TipRanks’ Stock Analysis page.